Post-Conference Perspectives: Managing R/R B-ALL with CAR T-Cell Therapy - Episode 3
R/R B-ALL: Key Efficacy Outcomes From the Updated Analysis of the ZUMA-3 Trial
Jae Park, MD, reviews updated data from the ZUMA-3 trial on the use of the CAR T-cell therapy brexucabtagene autoleucel (brexu-cel) for relapsed/refractory B-cell acute lymphoblastic leukemia, noting high remission rates, management of side effects like cytokine release syndrome, and post-CAR-T consolidation, including transplant.
